Dolasetron mesylate injection

Trade Name:

Anzemet

Manufacturer/Distributor:

Sanofi-Aventis Canada

1-800-267-7927 www.sanofi-aventis.ca

Classification:

Antiemetic

ATC Class:

A04AA04 - Dolasetron

Status:

discontinued

Notice of Compliance (yyyy/mm/dd):

2011/04/26

Date Marketed in Canada (yyyy/mm/dd):

2011/05/10

Presentation:

Inection: 20 mg/mL. DIN: 02231380

Comments:

The injectable form of dolasetron is being withdrawn from the Canadian market due to the potential risk of developing arrhythmias (prolongation of QTc interval) at doses used for prevention of nausea and vomiting in adults undergoing chemotherapy. The tablets will still be available as the risk of developing an abnormal heart rhythm is less than seen with the injectable from.

Keywords:

dolasetron mesylate

Keywords:

arrhythmia

Keywords:

intravenous drug administration

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Aztreonam	Cayston	Antibacterial	2009/11/11
Baloxavir marboxil	Xofluza	Antiviral agent	2020/02/19
Baricitinib	Olumiant	Immunosuppressant	2018/08/17
Belimumab	Benlysta	Immunosuppressant	2011/10/01
Bendamustine	Treanda	Antineoplastic agent	2012/09/12
Benralizumab	Fasenra	Respiratory agent	2018/03/28
Benzocaine	Orajel teething products		2018/05/23
Besifloxacin	Besivance	Fluoroquinolone	2010/01/27
Betamethasone valerate	Beteflam	Anti-inflammatory agent	2016/04/05
Bilastine	Blexten	Antihistamine	2016/12/02
Boceprevir	Victrelis	Hepatitis C virus protease inhibitor	2011/07/29
Brexpiprazole	Rexulti	Antipsychotic agent	2017/04/20
Brigatinib	Alunbrig	Antineoplastic agent	2018/07/26
Brimonidine	Onreltea	alpha-2 adrenergic receptor antagonist for rosacea	2014/04/23
Brivaracetam	Brivlera	Antiepileptic agent	2016/05/10
Brolucizumab	Beovu	Antineovascularisation agent	2020/05/15
Buprenorphine	BuTrans	Opioid analgesic	2010/03/05
Buprenorphine	Belbuca	Opioid analgesic	2018/01/17
Buprenorphine	Probuphine	Opiate partial agonist	2018/04/18
Buprenorphine	Sublocade	Partial opioid agonist	2019
Burosumab	Crysvita	Fibroblast growth factor 23 (FGF23) Inhibitor	2018/12/05
C1 esterase inhibitor, human	Berinert	C1-inhibitor	2010/10/08
Cabazitaxel	Jevtana	Antineoplastic agent	2011/06
Cabotegravir	Vocabria	Antiretroviral agent	2020/03/19
Cabotegravir + rilpivirine	Cabenuva	Antiretroviral agent	2020/03/19
Cabozantinib	Cabometyx	Antineoplastic agent	2018/09/14
Calcitonin salmon nasal spray	Miacalcin NS, Sandoz Calcitonin NS, Apo-Calcitonin NS	Bone metabolism regulator
Calcitriol	Rocaltrol oral solution	Vitamin D analogue
Canagliflozin	Invokana	antihyperglycemic agent	2014/06/25
Canakinumab	Ilaris	Immunomodulatory agent - selective interleukin-1 beta inhibitor	2010/05/03
Caplacizumab	Cablivi	Antithrombotic agent	2020/09/04
Cefotaxime	Claforan	Cephalosporin antibiotic	2016/11/09
Ceftobiprole	Zevtera	Cephalosporin antibiotic	2018/03/20
Ceftobiprole medocaril	Zeftera	Cephalosporin antibiotic	2010/04/16
Cemiplimab	Libtayo	Antineoplastic agent	2019/05/24
Certolizumab pegol	Cimzia	Biological response modifier	2009/08/31